Conjugatable ligands are designed to enhance the immune response by targeting specific receptors or pathways. They are chemically modified to allow attachment to a peptide or protein using a chemical linker, thereby enhancing stability, bioavailability, and targeting precision. Conjugatable ligands mainly include cytosolic pattern recognition receptors (PRRs), C-type lectin receptors (CLRs), Toll-like receptors (TLRs), PRR agonists, and toxoid adjuvants. Developing conjugatable ligands that target various immune receptors is essential for effective targeted therapies and vaccine delivery systems.
Product Name | Catalog | Unit Size | Price |
---|---|---|---|
ODN 2006 Negative Control | CDAD24-065-T | 1 mg | INQUIRY |
ODN 2007 | CDAD24-061-T | 1 mg | INQUIRY |
ODN 2041 | CDAD24-081-T | 1 mg | INQUIRY |
ODN 2088 | CDAD24-077-T | 1 mg, 5 mg | INQUIRY |
ODN 2088 Negative Control | CDAD24-078-T | 5 mg | INQUIRY |
ODN 2216 | CDAD24-046-T | 200 µg | INQUIRY |
ODN 2216 Biotin Conjugate | CDAD24-047-T | 50 µg | INQUIRY |
ODN 2216 FITC Conjugate | CDAD24-048-T | 50 µg | INQUIRY |
ODN 2336 | CDAD24-049-T | 1 mg, 5 mg | INQUIRY |
ODN 2336 Biotin Conjugate | CDAD24-051-T | 50 µg | INQUIRY |
ODN 2336 FITC Conjugate | CDAD24-052-T | 50 µg | INQUIRY |
ODN 2336 Negative Control | CDAD24-050-T | 1 mg, 5 mg | INQUIRY |
ODN 2395 | CDAD24-068-T | 1 mg, 5 mg | INQUIRY |
ODN 2395 Biotin Conjugate | CDAD24-070-T | 50 µg | INQUIRY |
ODN 2395 FITC Conjugate | CDAD24-071-T | 50 µg | INQUIRY |
ODN 2395 Negative Control | CDAD24-069-T | 5 mg | INQUIRY |
ODN 24888 | CDAD24-079-T | 1 mg, mg, 10 mg | INQUIRY |
ODN D-SL01 | CDAD24-062-T | 200 µg | INQUIRY |
ODN D-SL03 | CDAD24-076-T | 200 µg | INQUIRY |
ODN INH-1 | CDAD24-080-T | 200 µg | INQUIRY |